Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos; Iason Psilopatis; Anna Garmpi; Dimitrios Dimitroulis; Konstantinos Nikolettos; Kleio Vrettou; Panagiotis Sarantis; Evangelos Koustas; Gregory Kouraklis; Efstathios A. Antoniou; Michail V. Karamouzis; Nikolaos Nikolettos; Panagiotis Tsikouras; Georgios Marinos; Emmanouil Kontomanolis; Konstantinos Kontzoglou; Nikolaos Garmpis

doi:10.3390/cancers16010209

Cancers (Jan 2024)

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos,
Iason Psilopatis,
Anna Garmpi,
Dimitrios Dimitroulis,
Konstantinos Nikolettos,
Kleio Vrettou,
Panagiotis Sarantis,
Evangelos Koustas,
Gregory Kouraklis,
Efstathios A. Antoniou,
Michail V. Karamouzis,
Nikolaos Nikolettos,
Panagiotis Tsikouras,
Georgios Marinos,
Emmanouil Kontomanolis,
Konstantinos Kontzoglou,
Nikolaos Garmpis

Affiliations

Christos Damaskos: Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
Iason Psilopatis: Department of Obstetrics and Gynecology, University Erlangen, Universitaetsstrasse 21–23, 91054 Erlangen, Germany
Anna Garmpi: First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dimitrios Dimitroulis: Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Konstantinos Nikolettos: Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Kleio Vrettou: Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece
Panagiotis Sarantis: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Evangelos Koustas: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Gregory Kouraklis: Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Efstathios A. Antoniou: N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Michail V. Karamouzis: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Nikolaos Nikolettos: Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Panagiotis Tsikouras: Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Georgios Marinos: Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Greece
Emmanouil Kontomanolis: Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Konstantinos Kontzoglou: N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Nikolaos Garmpis: N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

DOI: https://doi.org/10.3390/cancers16010209
Journal volume & issue: Vol. 16, no. 1
p. 209

Abstract

Read online

Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords